RetigabineActivator of voltage-gated potassium channel, an anticonvulsant agent CAS# 150812-12-7 |
- Radicicol
Catalog No.:BCC2131
CAS No.:12772-57-5
- NVP-BEP800
Catalog No.:BCC2129
CAS No.:847559-80-2
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- IPI-504 (Retaspimycin hydrochloride)
Catalog No.:BCC2126
CAS No.:857402-63-2
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
- MPC-3100
Catalog No.:BCC2128
CAS No.:958025-66-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 150812-12-7 | SDF | Download SDF |
| PubChem ID | 121892 | Appearance | Powder |
| Formula | C16H18FN3O2 | M.Wt | 303.33 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | >12.95mg/mL in DMSO | ||
| Chemical Name | ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate | ||
| SMILES | CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N | ||
| Standard InChIKey | PCOBBVZJEWWZFR-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | KV7 (KCNQ) channel activator (EC50 values are 0.6 - 100 μM for KV7.1 - KV7.5). Anticonvulsant. Orally bioavailable. |
Retigabine Dilution Calculator
Retigabine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2967 mL | 16.4837 mL | 32.9674 mL | 65.9348 mL | 82.4185 mL |
| 5 mM | 0.6593 mL | 3.2967 mL | 6.5935 mL | 13.187 mL | 16.4837 mL |
| 10 mM | 0.3297 mL | 1.6484 mL | 3.2967 mL | 6.5935 mL | 8.2418 mL |
| 50 mM | 0.0659 mL | 0.3297 mL | 0.6593 mL | 1.3187 mL | 1.6484 mL |
| 100 mM | 0.033 mL | 0.1648 mL | 0.3297 mL | 0.6593 mL | 0.8242 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tropicamide
Catalog No.:BCC4574
CAS No.:1508-75-4
- Oxybutynin chloride
Catalog No.:BCC4149
CAS No.:1508-65-2
- Gap19
Catalog No.:BCC5599
CAS No.:1507930-57-5
- Drynachromoside A
Catalog No.:BCN7891
CAS No.:1507388-29-5
- Calyxamine B
Catalog No.:BCN1671
CAS No.:150710-72-8
- 5-Methoxycanthin-6-one
Catalog No.:BCN3326
CAS No.:15071-56-4
- Tolvaptan
Catalog No.:BCC5096
CAS No.:150683-30-0
- Fmoc-Lys(Dde)-OH
Catalog No.:BCC3518
CAS No.:150629-67-7
- epi-Eudesmol
Catalog No.:BCN1670
CAS No.:15051-81-7
- L-NIL hydrochloride
Catalog No.:BCC5706
CAS No.:150403-89-7
- o-Methoxycinnamaldehyde
Catalog No.:BCN3860
CAS No.:1504-74-1
- Pemetrexed disodium
Catalog No.:BCN2179
CAS No.:150399-23-8
- Retigabine dihydrochloride
Catalog No.:BCC1890
CAS No.:150812-13-8
- 2,3,24-Trihydroxyolean-12-en-28-oic acid
Catalog No.:BCN1559
CAS No.:150821-16-2
- Nitenpyram
Catalog No.:BCC5559
CAS No.:150824-47-8
- EGF816
Catalog No.:BCC6428
CAS No.:1508250-71-2
- Boc-Orn(Fmoc)-OH
Catalog No.:BCC3429
CAS No.:150828-96-9
- Micromelin
Catalog No.:BCN1672
CAS No.:15085-71-9
- Uralenol-3-methylether
Catalog No.:BCN7993
CAS No.:150853-98-8
- Bis(phenylacetyl) disulfide
Catalog No.:BCC8887
CAS No.:15088-78-5
- Euonymine
Catalog No.:BCN3084
CAS No.:150881-01-9
- Aurantiamide benzoate
Catalog No.:BCN8043
CAS No.:150881-02-0
- D-allo-Ile-OH
Catalog No.:BCC2966
CAS No.:1509-35-9
- Tirofiban hydrochloride monohydrate
Catalog No.:BCC2003
CAS No.:150915-40-5
The anticonvulsant retigabine suppresses neuronal KV2-mediated currents.[Pubmed:27734968]
Sci Rep. 2016 Oct 13;6:35080.
Enhancement of neuronal M-currents, generated through KV7.2-KV7.5 channels, has gained much interest for its potential in developing treatments for hyperexcitability-related disorders such as epilepsy. Retigabine, a KV7 channel opener, has proven to be an effective anticonvulsant and has recently also gained attention due to its neuroprotective properties. In the present study, we found that the auxiliary KCNE2 subunit reduced the KV7.2-KV7.3 Retigabine sensitivity approximately 5-fold. In addition, using both mammalian expression systems and cultured hippocampal neurons we determined that low muM Retigabine concentrations had 'off-target' effects on KV2.1 channels which have recently been implicated in apoptosis. Clinical Retigabine concentrations (0.3-3 muM) inhibited KV2.1 channel function upon prolonged exposure. The suppression of the KV2.1 conductance was only partially reversible. Our results identified KV2.1 as a new molecular target for Retigabine, thus giving a potential explanation for Retigabine's neuroprotective properties.
Retigabine diminishes the effects of acetylcholine, adrenaline and adrenergic agonists on the spontaneous activity of guinea pig smooth muscle strips in vitro.[Pubmed:28041987]
Auton Neurosci. 2017 Mar;203:51-57.
PURPOSE: The aim of this study is to evaluate the effect of Retigabine on the smooth muscle response to acetylcholine, adrenaline, alpha-and beta-adrenoceptor agonists. METHODS: We studied the change in the spontaneous smooth muscle contraction of guinea pig gastric corpus strips before and after 20-min treatment with 2muM Retigabine. We also evaluated the effect of Retigabine on the smooth muscle response to 10muM acetylcholine, 1 and 10muM adrenaline, 1muM methoxamine, 0.1muM p-iodoclonidine and 10muM isoproterenol. RESULTS: We observed a significant reduction in the effects of all studied mediators and agonists when they were added to organ baths in the presence of Retigabine. Retigabine diminished the effect of acetylcholine on the spontaneous smooth muscle activity. The effect was fully antagonized by XE-991 (Kv7 channel blocker), which supports our hypothesis about the role of KCNQ channels in the registered changes. The increase in the contraction force after adding of 1muM adrenaline, methoxamine, and 0.1muM p-iodoclonidine was also significantly smaller in presence of Retigabine. However, comparing the effect of 10muM adrenaline on the contractility before and after treatment with Retigabine, we observed increased contractility when Retigabine was present in the organ baths. CONCLUSION: A possible explanation for the observed diminished effects of mediators and receptor agonists is that the effect of Retigabine on smooth muscle contractility is complex. The membrane hyperpolarization, the interaction between Kv7 channels and adrenoceptors, and the influence on signaling pathways may contribute to the summary smooth muscle response.
Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.[Pubmed:27877093]
J Pediatr Pharmacol Ther. 2016 Sep-Oct;21(5):404-412.
OBJECTIVES: To explore the pharmacokinetic (PK) profile and safety of ezogabine (EZG)/Retigabine (RTG) as adjunctive therapy for uncontrolled partial-onset seizures (POS) in adolescents. METHODS: In this multiple-dose study (NCT01494584), adolescents with POS received EZG/RTG immediate-release tablets three times daily (TID) as adjunctive therapy to 1 to 3 concurrent antiepileptic drugs. The study comprised a screening phase, and a 5- to 8-week treatment phase starting with 100 mg TID up-titrated once weekly by
